sq-11725 has been researched along with Down Syndrome in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dang, V; Das, D; Lin, B; Martin, KJ; Medina, B; Moghadam, S; Naik, P; Nosheny, R; Patel, D; Salehi, A; Wesson Ashford, J | 1 |
1 other study(ies) available for sq-11725 and Down Syndrome
| Article | Year |
|---|---|
Formoterol, a long-acting β2 adrenergic agonist, improves cognitive function and promotes dendritic complexity in a mouse model of Down syndrome.
Topics: Adrenergic beta-2 Receptor Agonists; Adrenergic beta-Antagonists; Animals; Cell Proliferation; Dendrites; Disease Models, Animal; Doublecortin Domain Proteins; Down Syndrome; Ethanolamines; Fibroblast Growth Factor 2; Formoterol Fumarate; Gene Expression Regulation; Hippocampus; Humans; Male; Mice; Mice, Transgenic; Microtubule-Associated Proteins; Nadolol; Neurons; Neuropeptides; Receptors, Adrenergic, beta-2; Synaptophysin | 2014 |